Baxter Healthcare recalled 27,072 IV infusion sets on August 29, 2025, due to potential leaks. The affected product, model code 2R8858, may pose significant risks to patients. Healthcare providers and patients should stop using these devices immediately.
IV sets may leak.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Baxter Healthcare Corporation or your healthcare provider for instructions
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves the CLEARLINK System Paclitaxel Set, Non-Vented with Polyethylene Lined Tubing. It includes a CLEARLINK Luer Activated Valve and a 0.2 Micron Filter, with a length of 107 inches (2.7 meters). These devices were distributed nationwide in the United States.
The recalled IV sets may leak, posing a risk of inadequate drug delivery or exposure to the drug. This issue falls under Class II, indicating a potentially harmful situation.
As of now, there have been no reported injuries or deaths linked to the recalled IV sets. The leak could result in serious health complications if not addressed.
Stop using the recalled IV infusion sets immediately. Contact Baxter Healthcare Corporation or your healthcare provider for further instructions on the recall.
For more information, visit the recall notice at the FDA website or contact Baxter Healthcare Corporation directly.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.